Publicaciones en colaboración con investigadores/as de Hospital Universitario La Fe (10)

2024

  1. Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study

    Clinical and Translational Oncology, Vol. 26, Núm. 8, pp. 1896-1907

2023

  1. Expert consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the determination of biomarkers in pancreatic and biliary tract cancer

    Revista Espanola de Patologia, Vol. 56, Núm. 1, pp. 32-44

  2. SEOM-GEMCAD-TTD clinical guidelines for the systemic treatment of metastatic colorectal cancer (2022)

    Clinical and Translational Oncology, Vol. 25, Núm. 9, pp. 2718-2731

2022

  1. Evolution of RAS Mutations in Cell-Free DNA of Patients with Tissue RAS Wild-Type Metastatic Colorectal Cancer Receiving First-Line Treatment: The PERSEIDA Study

    Cancers, Vol. 14, Núm. 24

  2. Expert consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the determination of biomarkers in pancreatic and biliary tract cancer

    Clinical and Translational Oncology, Vol. 24, Núm. 11, pp. 2107-2119

2020

  1. Correlation of recist, computed tomography morphological response, and pathological regression in hepatic metastasis secondary to colorectal cancer: The avamet study

    Cancers, Vol. 12, Núm. 8, pp. 1-12

2019

  1. Update of metastatic colorectal cancer metastases resection after FOLFIRI-aflibercept in oxaliplatin-refractory patients

    Annals of Oncology, Vol. 30, pp. iv51-iv52

2015

  1. Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: A retrospective cross-sectional analysis

    BMC Cancer, Vol. 15, Núm. 1

  2. SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer 2015

    Clinical and Translational Oncology, Vol. 17, Núm. 12, pp. 972-981

2011

  1. Consenso de la Sociedad Española de Anatomía Patológica (SEAP) y de la Sociedad Española de Oncología Médica (SEOM) sobre la determinación de HER2 en el carcinoma gástrico

    Revista Espanola de Patologia, Vol. 44, Núm. 1, pp. 32-48